摩根大通：中国生物制药_ 哪些因素可能推动再鼎医药和君实生物股价上涨

China Biopharma What could have driven the share price rally of RemeGen and Junshi On June 12, RemeGen A/H stock jumped ~18%/20%, and Junshi A/H stock jumped ~6%/12%, significantly outperforming the overall market (Hang Seng Biotech Index +4.3%). Both companies have PD-1xVEGF bispecific antibodies (bsAbs) in development. We are providing the current development status of these bsAbs and sharing our insights. Considering that several biotech companies, such as RemeGen, Kelun-Biotech, Keymed, and Boan Biotech ...